Patient-derived microtumors with preserved immune competence

Clinically predictive models for advancing immuno-oncology drug development

Exclusive access to the only model worldwide with autologous TILs for true clinical relevance ✓ More reliable prediction of therapeutic response through preserved immune competence ✓ Broad use across solid tumors to accelerate and de-risk immunotherapy programs ✓